Menu
Search
|

Menu

Close
X

Aldeyra Therapeutics Inc ALDX.OQ (NASDAQ Stock Exchange Capital Market)

5.89 USD
-- (--)
As of Sep 17
Previous Close 5.89
Open --
Volume --
3m Avg Volume 59,383
Today’s High --
Today’s Low --
52 Week High 16.70
52 Week Low 4.31
Shares Outstanding (mil) 18.60
Market Capitalization (mil) 136.71
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.57 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
-0.578
FY18
-1.812
FY17
-1.403
FY16
-1.669
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
--
7.91
Price to Book (MRQ)
vs sector
4.77
5.38
Price to Cash Flow (TTM)
vs sector
--
24.36
Total Debt to Equity (MRQ)
vs sector
5.68
14.55
LT Debt to Equity (MRQ)
vs sector
4.35
10.20
Return on Investment (TTM)
vs sector
-72.27
14.48
Return on Equity (TTM)
vs sector
-75.02
15.78

EXECUTIVE LEADERSHIP

Richard Douglas
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Todd Brady
President, Chief Executive Officer, Director, Since 2012
Salary: $506,000.00
Bonus: $253,000.00
Joshua Reed
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Stephen Machatha
Senior Vice President, Technical Operations, Since 2019
Salary: --
Bonus: --
David Clark
Chief Medical Officer, Since 2016
Salary: $424,445.00
Bonus: $133,700.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

131 Hartwell Ave Ste 320
LEXINGTON   MA   02421-3105

Phone: +1781.7614904

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.

SPONSORED STORIES